Stance Capital’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
Other funds holding MRNA
VCM
VPM
Stance Capital's MRNA Position: Q1 2026 in Review
Stance Capital opened a new position in Moderna (MRNA) in Q1 2026: 569 shares worth $28.9K. The stake represents 0.01% of the portfolio and ranks #196 among its holdings. This is a return to the name: Stance Capital previously reported a position in MRNA as recently as Q3 2025.
Stance Capital first reported a position in MRNA in Q4 2024 and has held it in 3 quarters since. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.
- Stance Capital held 569 shares of Moderna worth $28.9K as of Q1 2026.
- Moderna was a new Stance Capital position in Q1 2026.
- Moderna made up 0.01% of Stance Capital's portfolio in Q1 2026, its #196 holding.
- Stance Capital first reported a position in Moderna in Q4 2024 and has held it in 3 quarters since.
- 723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.
Based on Stance Capital's 13F filing for Q1 2026, filed 14 May 2026.